When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BPMC - Blueprint Medicines files U.S. application for pralsetinib for thyroid cancer
Blueprint Medicines Corporation
Blueprint Medicines (NASDAQ:BPMC) has submitted a marketing application to the FDA seeking approval of RET inhibitor pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancers.
More news on: Blueprint Medicines Corporation, Healthcare stocks news,